Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today
announced that Peter Greenleaf will join Sucampo as Chief Executive
Officer ("CEO") and as a member of the Board of Directors ("Board")
on March 3, 2014. Mr. Greenleaf, 43, brings to Sucampo more than 20
years of experience in commercialization and drug development in
the biopharmaceutical industry.
A photo accompanying this release is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=23524
Ryuji Ueno, M.D., Ph.D., Ph.D. will step down as CEO, Chairman
of the Board, and member of the Board when Mr. Greenleaf joins
Sucampo. In addition, Dr. Ueno will step down as Chief Scientific
Officer on March 31, 2014. As Co-Founder, Chairman Emeritus,
and Scientific Advisor, Dr. Ueno will provide consulting services
to ensure a smooth transition and advise Sucampo on the development
of its pipeline and other strategic activities, through a one-year,
renewable contract.
In addition, Dan Getman, Ph.D. has been named Chairman of the
Board, effective March 3, 2014. Dr. Getman has been a Director
of Sucampo since 2011 and is the current Chairman of Sucampo's
Science and Technology Committee, as well as Chairman and/or member
of other Board committees.
"Peter's expertise in growing biopharmaceutical companies,
including experience leading a gastroenterology business, will be a
valuable addition to Sucampo. The Board is confident that
under his leadership Sucampo's legacy of growth will be
accelerated," said Dr. Getman. "Peter brings the right mix of
commercial, strategic planning, and product development expertise
that we believe will enhance the value of Sucampo's proprietary
prostone technology and its delivery to patients and healthcare
providers around the world. On behalf of the entire Board, I
also want to thank Dr. Ueno for his visionary leadership and the
strong scientific foundation he established for Sucampo. His
breakthrough discovery of the therapeutic potential of prostones
led to the development and approval of two products, and it
established Sucampo as a global biopharmaceutical company whose
medicines have benefited millions of patients across three
continents."
Dr. Ueno stated, "I believe that Peter brings the right
experience to lead Sucampo during this pivotal time. I look
forward to supporting him and the management team as they expand
the potential of Sucampo's prostone technology, which has resulted
in two approved products marketed globally."
Mr. Greenleaf is the President, CEO and Board member of
Histogenics, a regenerative medicine company. Prior to his
leadership of Histogenics, Mr. Greenleaf served as President of
MedImmune, the global biologics arm of AstraZeneca, where he was
instrumental in driving the expansion of MedImmune's pipeline into
over 120 clinical and pre-clinical programs and the
commercialization of its marketed products. Mr. Greenleaf also
served as President of MedImmune Ventures, a wholly owned venture
capital fund within the AstraZeneca Group, where he led investment
in emerging biopharmaceutical, medical device, and diagnostic
companies.
"I am excited to join Sucampo at this critical time in the
company's growth," said Mr. Greenleaf. "Sucampo has evolved
into a global biopharmaceutical company with products approved on
three continents. And, with its rich pipeline, the company is
poised to harness the significant potential of its prostone
technology via additional therapeutic areas that can address a
greater number of unmet patient needs. I look forward to
working with Dr. Ueno, the management team and the Board of
Directors to ensure that Sucampo's ongoing commitment to deliver
patient, physician and shareholder value continues to expand and
grow."
Prior to serving as President of MedImmune, Mr. Greenleaf was
the Chief Commercial Officer of the company, responsible for its
commercial, corporate development and strategy functions. Mr.
Greenleaf has also held senior commercial roles at Centocor,
leading the company's gastroenterology division, and has additional
experience at Boehringer Mannheim and Hallmark Cards,
Inc.
Mr. Greenleaf currently chairs the Maryland Venture Fund
Authority, whose vision is to oversee implementation of
InvestMaryland, a public-private partnership to spur venture
capital investment in the state. Mr. Greenleaf's previous
Board appointments include the Biotechnology Industry Organization
("BIO"); the University of Maryland Baltimore Foundation, Inc.;
Rib-X Pharmaceuticals; LigoCyte Pharmaceuticals; and Corridor
Pharmaceuticals. He received a Master of Business
Administration degree from St. Joseph's University and a Bachelor
of Science degree from Western Connecticut State University.
Dr. Getman was a Vice President of global research and
development at Pfizer and Director of the company's St. Louis
Laboratories, which played a key role in the company's
biotherapeutics, inflammation research, and indications
discovery. Dr. Getman has also held senior positions at
Pharmacia, Searle, and Monsanto in research and development and
medicinal chemistry, and he is the former Chairman of the Missouri
Biotechnology Association (MOBIO). Dr. Getman earned a Ph.D.
in Organic Chemistry from the University of Minnesota, in
Minneapolis, and a Bachelor of Science degree in Chemistry from
SUNY Buffalo.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical
company focused on innovative research, discovery, development and
commercialization of proprietary drugs based on prostones.
The therapeutic potential of prostones was first discovered
by Ryuji Ueno, M.D., Ph.D., Ph.D., co-founder of Sucampo.
Prostones, naturally occurring fatty acid metabolites that
have emerged as promising compounds with unique physiological
activities, can be targeted for the treatment of unmet or
underserved medical needs. Sucampo has two marketed
products – AMITIZA® and RESCULA® – and a pipeline of prostone-based
product candidates in clinical development. A global company,
Sucampo is headquartered in Bethesda, Maryland, and has operations
in Japan, the United Kingdom and Switzerland. For more information,
please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG. RESCULA is a registered trademark of
R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, future financial
and operating results, and other statements that are not historical
facts. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and
health care legislation; Sucampo's ability to accurately predict
future market conditions; dependence on the effectiveness of
Sucampo's patents and other protections for innovative products;
the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or
regulatory actions. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected.
Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in
Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates
by reference.
Follow us on Twitter (@Sucampo_Pharma). Follow us on Linkedin
(Sucampo Pharmaceuticals).
Twitter LinkedIn
The photo is also available at Newscom, www.newscom.com, and via
AP PhotoExpress.
CONTACT: Silvia Taylor
Senior Vice President, Investor Relations, PR,
and Corporate Communications
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Jul 2023 to Jul 2024